Abstract 1120
Background
Brigatinib is a next-generation ALK inhibitor with activity against a broad range of ALK mutations and ROS1 rearrangements. It is approved for use post-crizotinib in ALK+ mNSCLC based on phase II trial (ALTA) data, and significantly improved progression-free survival (PFS) vs crizotinib (HR = 0.49) in ALK TKI-naïve patients (pts) in the phase III ALTA-1L trial. UVEA-Brig captures detailed information about brigatinib therapy in a real-world situation.
Methods
UVEA-Brig is a retrospective analysis of data from pts who started brigatinib between 06/16 and 12/17 in Italy, Norway, Spain and the UK in an expanded access program (EAP). Due to legislation in Italy, only data for deceased pts and pts who had been followed up for 18 months could be used. Adults with mNSCLC, including those with brain lesions, who are resistant to or intolerant of at least one prior ALK inhibitor and have ECOG performance status ≤3 are eligible. The primary objective is to describe baseline characteristics, prior therapy, clinical outcomes and safety with brigatinib.
Results
Data for 50 pts are available (male: 40%; never smoker: 54%; adenocarcinoma: 94%: stage IV at diagnosis: 92%; median age: 51 [31–78] years; brain lesions at study entry: 60% [46% irradiated]). Median follow-up 6 (range 0–24) months. Pts had received a median of 2 (range 1–6) lines of prior systemic therapy (≥3 lines: 34%), with a median of 1 (1–5) prior ALK TKI (crizotinib 84%; ceritinib 46%; alectinib 10%; lorlatinib 8%). 36 pts have discontinued brigatinib (progression: 25; adverse events: 3 [pneumonitis, amylase and creatine kinase increase, and asthenia/fatigue]). 43 pts were evaluable for best response: complete response: 1 (2.3%); partial response: 14 (32.6%); stable disease: 20 (46.5%) (response rate: 34.9%; disease control rate: 81.4%). Median response duration was 9.7 (range 0.7–23.4) months. Median PFS was 5.7 (95% CI 6.2–9.9) months; median OS was 10.2 (8.6–12.6) months. 20 pts received subsequent therapies; 17 had an ALK inhibitor, most commonly lorlatinib (n = 10).
Conclusions
These data from daily clinical practice support the activity of brigatinib also in pts with heavily pretreated ALK+ mNSCLC.
Clinical trial identification
Editorial acknowledgement
Andrew Noble, Bioscript Group.
Legal entity responsible for the study
Takeda.
Funding
Takeda.
Disclosure
S. Novello: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda, BMS, Moehringer Ingelheim, Eli Lilly, Celgene, Pfizer, Roche, AstraZeneca, MSD, AbbVie. O.T. Brustugun: Honoraria (institution): Takeda. J. Cadranel: Advisory / Consultancy: Takeda; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Roche. F. Griesinger: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Takeda; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Siemens; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ariad; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AbbVie. M.J. Hochmair: Honoraria (self): AstraZeneca; Honoraria (self): BMS; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self): Pfizer; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Takeda; Advisory / Consultancy: Novartis. M. Pérol: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Takeda. S. Popat: Honoraria (self), Research grant / Funding (institution): BMS, Roche, Takeda, Pfizer, MSD, EMD Serono, Boehringer Ingelheim; Honoraria (self): Chugai, Novartis, Guardant Health, AbbVie, Medscape, Tesaro, OncLive, AstraZeneca; Research grant / Funding (institution): Bayer, Celgene, Synta, Clovis Oncology, Eli Lilly, Epizyne, Ariad; Research grant / Funding (self): Elsevier. N. Bent-Ennakhil: Full / Part-time employment: Takeda. C. Kruhl: Full / Part-time employment: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract